America Pharma Source (Apharmas) has launched next generation in vitro transfection reagents, Easy-Transgater and Easy-Transgater-si, specifically developed for the delivery of DNA/RNA and siRNA into difficult-to-transfect cell lines as well as a broad range of mammalian cells. Based on new lipid-conjugation technology, these products have superior transfection efficiency with low cytotoxicity and no sera interference.
Gaithersburg, MD (PRWEB) July 9, 2004 -- America Pharma Source, LLC (Apharmas) today announced that it has launched next generation in vitro transfection reagents, Easy-Transgater and Easy-Transgater-si, specifically developed for the delivery of DNA/RNA and siRNA into difficult-to-transfect cell lines as well as a broad range of mammalian cells. These products are based on new lipid-conjugation technology and have superior transfection efficiency with low cytotoxicity and no sera interference. Their simple protocols enable researchers to get satisfactory results easily and fast. Along with the introduction of these products, Apharmas also announced the launch of pre-coated ready-to-transfect plates (96-well, 24-well and 6-well) for high-throughput applications such as screening and gene silencing.
"To effectively deliver genes to cells, both in vitro and in vivo, still faces many technical problems and challenges, especially in RNAi and gene therapy area. Apharmas is working hard to develop gene/drug delivery systems and provide more powerful transfection tools. Easy-Transgater series are the result of our initial efforts," said Dr. Frank F. Yu, CEO of America Pharma Source. With the introduction of these products, researchers now have better choices for difficult-to-transfect cell lines and high-throughput applications. More importantly, comparing to the most popular transfection products, Easy-Transgater series can save 20% to 40% reagent costs. Apharmas believes that will greatly benefit those academic institutes, universities and small biotech companies. We are continuing to offer more innovative products for transfection into primary cells to satisfy the growing demand for siRNA and DNA/RNA delivery tools."
About Apharmas:
America Pharma Source (Apharmas) is a growing biopharma company to provide products and services to pharmaceutical and biotech companies, universities and non-profit organizations to accelerate their bioscience research and drug development efforts. Working with strategic research partners, Apharmas also is developing new technologies and products on drug delivery system to discover new combinations and seek a balanced therapy. Founded in 2000, Apharmas has expanded its presence in Asia market and established a R&D and manufacture facility in China. For more information about Apharmas, visit the companys web site at www.apharmas.com.
Contacts:
PR Specialist
America Pharma Source
240-632-9478
E-mail: pr@apharmas.com
This press release may contain certain forward-looking statements regarding Apharmas's performance, including future products, or strategies or developments that Apharmas expects to occur or anticipates occurring in the future. Such statements are based upon current expectations that involve a number of business risks and uncertainties. Such uncertainties and risks include, but are not limited to, risks associated with management of growth, competition, technology, national and international operation, etc.
|
